The Journal of Practical Medicine >
Current research status and clinical application progress of the immune checkpoint LAG⁃3 and its targeting drugs
Received date: 2023-09-21
Online published: 2024-06-13
Lymphocyte-activation gene 3 （LAG-3） is an inhibitory immune checkpoint receptor that negatively regulates the function of T cells to prevent over-activation of the immune system from damaging human body. In the existence of tumors and chronic infections， persistent antigenic stimulation induces upregulation of LAG-3 expression in effector T cells， leading to T cell exhaustion and tumor immune escape. Targeting LAG-3 drugs can reactivate the anti-tumor function of T cells by specifically blocking the signaling pathway of LAG-3， and have shown promising efficacy in a variety of solid tumors， hematologic tumors and autoimmune diseases. In this paper， we summarize the current research progress on the structure， ligand and regulatory function of LAG-3， review the current status of clinical trials of LAG-3-targeted drugs， and further discuss the clinical application strategy and development direction of LAG-3-targeted drugs， with a view to providing reference for further in-depth research on LAG-3.
Huinan ZHOU , Kewei QIN , Lijun. ZHOU . Current research status and clinical application progress of the immune checkpoint LAG⁃3 and its targeting drugs[J]. The Journal of Practical Medicine, 2024 , 40(11) : 1607 -1612 . DOI: 10.3969/j.issn.1006-5725.2024.11.024
| 1 | MING Q， CELIAS D P， WU C， et al. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition［J］. Nat Immunol， 2022，23（7）： 1031-1041. doi:10.1038/s41590-022-01238-7 |
| 2 | TRIEBEL F， JITSUKAWA S， BAIXERAS E， et al. LAG-3， a novel lymphocyte activation gene closely related to CD4［J］. J Exp Med， 1990，171（5）： 1393-1405. doi:10.1084/jem.171.5.1393 |
| 3 | WORKMAN C J， DUGGER K J， VIGNALI D A. Cutting edge： molecular analysis of the negative regulatory function of lymphocyte activation gene-3［J］. J Immunol， 2002，169（10）： 5392-5395. doi:10.4049/jimmunol.169.10.5392 |
| 4 | MAEDA T K， SUGIURA D， OKAZAKI I M， et al. Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation［J］. J Biol Chem， 2019，294（15）： 6017-6026. doi:10.1074/jbc.ra119.007455 |
| 5 | XU F， LIU J， LIU D， et al. LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses［J］. Cancer Res， 2014，74（13）： 3418-3428. doi:10.1158/0008-5472.can-13-2690 |
| 6 | KOUO T， HUANG L， PUCSEK A B， et al. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells［J］. Cancer Immunol Res， 2015，3（4）： 412-423. doi:10.1158/2326-6066.cir-14-0150 |
| 7 | WANG J， SANMAMED M F， DATAR I， et al. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3［J］. Cell， 2019，176（1-2）： 334-347. doi:10.1016/j.cell.2018.11.010 |
| 8 | 贾王强， 倪红谚， 袁龙. FGL-1作为LAG-3主要的免疫抑制配体在恶性肿瘤中的研究进展［J］. 实用医学杂志， 2021，37（4）： 547-551. doi:10.3969/j.issn.1006-5725.2021.04.026 |
| 9 | MARUHASHI T， SUGIURA D， OKAZAKI I M， et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity［J］. Immunity， 2022，55（5）： 912-924. doi:10.1016/j.immuni.2022.03.013 |
| 10 | GUY C， MITREA D M， CHOU P， et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation［J］. Nat Immunol， 2022，23（5）： 757-767. doi:10.1038/s41590-022-01176-4 |
| 11 | MAO X， OU M T， KARUPPAGOUNDER S S， et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3［J］. Science， 2016，353（6307）：aah3374. |
| 12 | GREBINOSKI S， ZHANG Q， CILLO A R， et al. Autoreactive CD8（+） T cells are restrained by an exhaustion-like program that is maintained by LAG3［J］. Nat Immunol， 2022，23（6）： 868-877. doi:10.1038/s41590-022-01210-5 |
| 13 | KURACHI M. CD8（+） T cell exhaustion［J］. Semin Immunopathol， 2019，41（3）： 327-337. doi:10.1007/s00281-019-00744-5 |
| 14 | DAI E， ZHU Z， WAHED S， et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy［J］. Mol Cancer， 2021，20（1）： 171. doi:10.1186/s12943-021-01464-x |
| 15 | SUNG E， KO M， WON J， et al. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation［J］. Mol Ther， 2022，30（8）： 2800-2816. doi:10.1016/j.ymthe.2022.05.003 |
| 16 | CAMISASCHI C， DE FILIPPO A， BERETTA V， et al. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions： involvement of LAG-3［J］. J Invest Dermatol， 2014，134（7）： 1893-1902. doi:10.1038/jid.2014.29 |
| 17 | YANG L L， MAO L， WU H， et al. pDC depletion induced by CD317 blockade drives the antitumor immune response in head and neck squamous cell carcinoma［J］. Oral Oncol， 2019，96： 131-139. doi:10.1016/j.oraloncology.2019.07.019 |
| 18 | LIANG B， WORKMAN C， LEE J， et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II［J］. J Immunol， 2008，180（9）： 5916-5926. doi:10.4049/jimmunol.180.9.5916 |
| 19 | GHOSH S， SHARMA G， TRAVERS J， et al. TSR-033， a Novel Therapeutic Antibody Targeting LAG-3， Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo［J］. Mol Cancer Ther， 2019，18（3）： 632-641. doi:10.1158/1535-7163.mct-18-0836 |
| 20 | 邓俊， 王均， 高嫦娥， 等. 免疫检查点抑制剂毒性预测生物标志物的研究进展［J］. 实用医学杂志， 2023，39（20）： 2561-2565. doi:10.3969/j.issn.1006-5725.2023.20.001 |
| 21 | 张陈， 刘平， 于晓杰， 等. 新型全人源LAG3单克隆抗体的体外抗肿瘤作用及其机制初探［J］. 中国肿瘤生物治疗杂志， 2022，29（5）： 419-425. |
| 22 | PREVITE D M， MARTINS C P， O'CONNOR E C， et al. Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4（+） T Cells［J］. Cell Rep， 2019，27（1）： 129-141. doi:10.1016/j.celrep.2019.03.004 |
| 23 | HUANG R Y， FRANCOIS A， MCGRAY A R， et al. Compensatory upregulation of PD-1， LAG-3， and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer［J］. Oncoimmunology， 2017，6（1）： e1249561. doi:10.1080/2162402x.2016.1249561 |
| 24 | HUANG R Y， EPPOLITO C， LELE S， et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model［J］. Oncotarget， 2015，6（29）： 27359-27377. doi:10.18632/oncotarget.4751 |
| 25 | TAWBI H A， SCHADENDORF D， LIPSON E J， et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma［J］. N Engl J Med， 2022，386（1）： 24-34. doi:10.1056/nejmoa2109970 |
| 26 | AMARIA R N， POSTOW M， BURTON E M， et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma［J］. Nature， 2022，611（7934）： 155-160. doi:10.1038/s41586-022-05368-8 |
| 27 | WANG J B， QIU Q Z， ZHENG Q L， et al. Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer［J］. Adv Sci （Weinh）， 2023， 10（15）：e2207417. doi:10.1002/advs.202207417 |
| 28 | THUDIUM K， SELBY M， ZORN J A， et al. Preclinical Characterization of Relatlimab， a Human LAG-3-Blocking Antibody， Alone or in Combination with Nivolumab［J］. Cancer Immunol Res， 2022，10（10）： 1175-1189. doi:10.1158/2326-6066.cir-22-0057 |
| 29 | SANGRO B， NUMATA K， HUANG Y， et al. Relatlimab plus nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors， a phase 2， randomized， open-label study： RELATIVITY-073［J］. Ann Oncol， 2021，32： S117. doi:10.1016/j.annonc.2021.05.116 |
| 30 | HAMID O， WANG D， KIM T M， et al. Clinical activity of fianlimab （REGN3767）， a human anti-LAG-3 monoclonal antibody， combined with cemiplimab （anti-PD-1） in patients （pts） with advanced melanoma.［J］. J Clin Oncol， 2021，39（）：9515. doi:10.1200/jco.2021.39.15_suppl.9515 |
| 31 | HAMID O， LEWIS K D， WEISE A， et al. 400P Phase I study of fianlimab， a human lymphocyte activation gene-3 （LAG-3） monoclonal antibody， in combination with cemiplimab in advanced melanoma （mel）［J］. Ann Oncol， 2022，33： S1598. doi:10.1016/j.annonc.2022.10.431 |
| 32 | YU X， HUANG X， CHEN X， et al. Characterization of a novel anti-human lymphocyte activation gene 3 （LAG-3） antibody for cancer immunotherapy［J］. MAbs， 2019，11（6）： 1139-1148. doi:10.1080/19420862.2019.1629239 |
| 33 | SHI Y， LUO S， ZHOU H， et al. Phase I study of LBL-007， a novel anti-human lymphocyte activation gene 3 （LAG-3） antibody in patients with advanced solid tumors［J］. J Clin Oncol， 2021，39（）： 2523. doi:10.1200/jco.2021.39.15_suppl.2523 |
| 34 | BAI X， LI M， PU X X， et al. Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma： A phase.， open-label， multicenter， dose escalation/expansion study［J］. J Clin Oncol， 2022，40（）：9538. doi:10.1200/jco.2022.40.16_suppl.9538 |
| 35 | RADER C. Bispecific antibodies in cancer immunotherapy［J］. Curr Opin Biotechnol， 2020，65： 9-16. doi:10.1016/j.copbio.2019.11.020 |
| 36 | WANG J， ASCH A S， HAMAD N， et al. A Phase 1， Open-Label Study of MGD013， a Bispecific DART? Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma［J］. Blood， 2020，136： 21-22. doi:10.1182/blood-2020-139868 |
| 37 | OH D Y， BANG Y J. HER2-targeted therapies-a role beyond breast cancer［J］. Nat Rev Clin Oncol， 2020，17（1）： 33-48. doi:10.1038/s41571-019-0268-3 |
| 38 | CATENACCI D， ROSALES M K， CHUNG H， et al. P-342 Margetuximab combined with anti-PD-1 （MGA012） or anti-PD-1/LAG-3 （MGD013） +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer［J］. Ann Oncol， 2020， 31（3）：S201. doi:10.1016/j.annonc.2020.04.424 |
| 39 | KRAMAN M， FAROUDI M， ALLEN N L， et al. FS118， a Bispecific Antibody Targeting LAG-3 and PD-L1， Enhances T-Cell Activation Resulting in Potent Antitumor Activity［J］. Clin Cancer Res， 2020，26（13）： 3333-3344. doi:10.1158/1078-0432.ccr-19-3548 |
| 40 | YAP T A， LORUSSO P M， WONG D J， et al. A Phase 1 First-in-Human Study of FS118， a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance［J］. Clin Cancer Res， 2023，29（5）： 888-898. doi:10.1158/1078-0432.ccr-22-1449 |
| 41 | EDWARDS C J， SETTE A， COX C， et al. The multi-specific V（H）-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity［J］. Br J Cancer， 2022，126（8）： 1168-1177. doi:10.1038/s41416-021-01684-4 |
| 42 | LEGAT A， MABY-EL H H， BAUMGAERTNER P， et al. Vaccination with LAG-3Ig （IMP321） and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients-Report of a Phase I/IIa Clinical Trial［J］. Clin Cancer Res， 2016，22（6）： 1330-1340. doi:10.1158/1078-0432.ccr-15-1212 |
/
| 〈 |
|
〉 |